Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP

Status:
Not yet recruiting

Trial end date:
2025-11-30

Target enrollment:

Participant gender:

Evaluate the efficacy, safety, and PK of avatrombopag given for 26 weeks in Japanese adults with chronic immune thrombocytopenia (ITP).

Phase 3

Sobi, Inc.